Month: October 2012


Omeros, clinical stage biopharmaceutical company, announced on 10/3, the completion of enrollment in OMS302 phase 3 clinical trial. OMS302  is one of Omero’s proprietary PharmocoSurgery products. There has been a gain since last meeting, with a stock price of $10.80, up from around $9.00 last month. With only positive news and the the stock still …

$OMER Read More »


Altria group Inc, manufacturer of cigarettes, smokeless products, and wine in the US, is a P/E of 15.7 , below the average tobacco industry PE. Share are up 14.7%  year do date and all analysts rate it a hold. The next dividend payment date for MO is 10/10/2012. Press since the last meeting include “Altria …

$MO Read More »